Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis

Table 2

Baseline patient characteristics.

(a) Studies reporting median OS estimates

	AX	EX		DA	DE		Overall
Studies (count)	3	2		10	2		17
Sample Size	649	923		1920	993		4485
Race (count)
White	2	1		8	2		13
Asian	1	1		2	0		4
Age (median)	71.3	72.7		70.7	71.0		71.2
Baseline PSA (median)	184.0	32.7		113.6	107.7		107.7
Gleason score ≥ 8 (proportion)	42%	52%		53%	50%		39%
PSA decline ≥ 50% (proportion)	34%	77%		36%	53%		48%

(b) Studies reporting median PFS estimates

	AX	EX		DA	DE		Overall
Studies (count)	3	4		3	3		13
Sample size	615	498		1268	915		3296
Race (count)
White	3	3		3	2		11
Asian	1	1		2	0		2
Age (median)	70.6	71.2		73.0	68.4		70.6
Baseline PSA (median)	120.3	16.1		32.5	64.0		33.8
Gleason score ≥ 8 (proportion)	48%	56%		51%	52%		52%
PSA decline ≥ 50% (proportion)	30%	77%		38%	53%		47%

-tests with unequal variances values are shown for the comparisons between AX and EX and between DA and DE. Not enough information for the test.